Wolf Lisa G reported option exercise involving 4 shares of Valion Bio, Inc. on Sep 18, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
COO & CFO
COO & CFO
Filed Sep 24, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
4Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
29Direct
Trade date
Sep 18, 2026Option exercise
Filed
Sep 24, 2026, 4:45 PM ET6-day reporting delay
Accession
0001683168-26-007396Code M · Transaction 229141
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 18, 2026Tax withholding2$2.12−$4.24Trade 229142
Sep 18, 2026Option exercise4$0.00$0Trade 229143
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
2 warnings
delayed filingThe filing was reported 6 calendar days after the transaction date.
missing priceThe filing did not provide a usable price per share.

VBIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
VBIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Oct 1, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Each Restricted Stock Unit is convertible into one share of Common Stock. F2: The Reporting Person forfeited 2 shares of Common Stock upon vesting and settlement of 4 outstanding Restricted Stock Units to cover tax withholdings, using the market price of the Issuer's Common Stock at the time of forfeiture. F3: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. F4: These numbers have been adjusted to reflect the reverse stock split of the Common Stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026.